Delivery Order 36F79721D0166-36C26025F0296
Award Date
9/9/25
Potential Completion Date
9/8/26
Potential Value
$382K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Earth City, MO 63045, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for a delivery order under Biocryst Pharmaceuticals Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the U.S. Department of Veterans Affairs (VA). The award, valued at $387,618.82, is for the bulk ordering of ORLADEYO, a medication used to treat hereditary angioedema. The contract has an ultimate completion date of March 11, 2025. Biocryst Pharmaceuticals is a biotechnology company that specializes in developing small...
This federal contract award is for the delivery of BEROTRALSTAT HCL 150MG CAP (trade name ORLADEYO 150MG CAP) to the U.S. Department of Veterans Affairs (VA). The $379,348.93 contract was awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. This is a Firm Fixed Price delivery order placed under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an...
This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...
Biocryst Pharmaceuticals Inc. has received a $29,649.88 delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to supply berotralstat and berotralstat hydrochloride capsules. The delivery order was awarded against Biocryst's Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), and carries a completion date of May 16, 2024. No set-aside designation was used for this award. Biocryst will perform under...
Biocryst Pharmaceuticals, Inc. was awarded a $56,670.76 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The contract calls for the delivery of berotralstat to Roseburg, Oregon with a period of performance concluding on January 19, 2024. No set-aside designation was applied to this award issued against GSA Schedule 61-IB for pharmaceutical...
This is a firm fixed-price delivery order awarded to CSL Behring L.L.C., a foreign-owned, for-profit biotherapeutics company, by the U.S. Department of Veterans Affairs (VA). The contract is part of the VA's Federal Supply Schedule (FSS) for Pharmaceuticals and Drugs (FSS-61-IB), with a ceiling value of $75,295.97. The order is for pharmaceutical products, including medications like HAEGARDA, Privigen, Hizentra, and Kcentra, to support healthcare services for veterans across different VA medical...
This federal contract award is for the delivery of the drug HAEGARDA to the Department of Veterans Affairs (VA) Veterans Health Administration and its regional Veterans Integrated Service Networks. The prime contractor is CSL Behring L.L.C., a global biotherapeutics company focused on developing treatments for rare and serious medical conditions. The contract was awarded on a firm fixed price basis under CSL Behring's Pharmaceuticals and Drugs Federal Supply Schedule contract with the General...
This contract award is for the delivery of pharmaceutical drugs to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The prime contractor is CSL Behring L.L.C., doing business as CSL Behring LLC, a global biotherapeutics company. The contract has a potential value of $920,784.38 and is a firm fixed price delivery order against CSL Behring's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract with the General Services Administration (GSA). The...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...